Alchem Laboratories Corporation

Alachua, FL

UEI
LD2KY6H7KMQ5
CAGE
3E3D1
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
13305 Rachael Blvd, Alachua, FL 32615, USA
Website
alchem.com
Founded
1997
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $1,004,948
FY2025 $406,478
FY2024 -$15,419,852
FY2023 $1,195,060

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Department of Health and Human Services $1,004,948

Contract vehicles

Expired vehicles (3)

Contract awards

Latest 5 listed here. See the rest on GovTribe.

Grant awards

Grant subawards

Prime recipient Prime award Amount Awarded
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. AI-based screening of ultra-large chemical libraries to identify selective muscarinic receptor antagonists as peripheral neuropathy therapeutics HT94252510223 $299,222

Similar vendors

About the company

Alchem Laboratories Corporation, a for-profit pharmaceutical manufacturer based in Alachua, Florida, provides custom organic synthesis, cGMP manufacturing, analytical testing, and Chemistry, Manufacturing, and Controls (CMC) services for drug development and preclinical research to the National Institutes of Health as a prime contractor (97% of recent awards), competing full and open with no set-aside designations.

Alchem's customer footprint is heavily concentrated within HHS-NIH. The top five funding agencies account for 76% of awards by count and 92% by combined potential value, nearly entirely composed of NIH institutes and centers. The National Cancer Institute leads by award count (19 awards, $66.7 million combined potential value), but the National Institute of Allergy and Infectious Diseases and the National Institute on Drug Abuse dominate by dollar value ($157.3 million and $99.6 million, respectively). Alchem holds five active indefinite-delivery contracts anchoring this portfolio: a $50 million single-award IDIQ with NIAID for interventional agents chemistry services (awarded September 2024, running through September 2032); a $49.9 million multiple-award IDIQ with the National Institute of Neurological Disorders and Stroke for drug manufacturing and formulation under the Blueprint Neurotherapeutics Network (awarded May 2026, running through May 2036); two multiple-award IDIQs with NIDA worth approximately $49.7 million and $49.9 million for CMC services (awarded August 2024 and August 2026, respectively); and a $12.1 million single-award IDIQ with NCI for synthesis and analysis of GMP and non-GMP bulk drugs (awarded April 2023, running through April 2028). Recent delivery orders under the NCI IDIQ include a $4.1 million cost-plus-fixed-fee order (awarded September 2026, running through March 2032) for non-GMP compound synthesis and GMP/non-GMP bulk drug analysis, and a $2.3 million incremental order (awarded June 2022, running through June 2027) for non-GMP small-molecule synthesis and cGMP manufacturing. Alchem operates primarily as a prime (36 of 37 awards); its single subcontract is a grant sub-award with the Henry M. Jackson Foundation for research on muscarinic receptor antagonists for peripheral neuropathy therapeutics. On SCI-reportable service contracts, Alchem invoiced $376 thousand across 1.5 FTEs in FY2022, with zero SCI-reported activity in FY2024, reflecting the prevalence of manufacturing and goods delivery in its federal work. Activity has remained stable at one to four awards per year across the past five years, with two awards (combined potential value $2.3 million) reaching ultimate completion inside the next twenty-four months. The vendor's NAICS distribution tilts toward Pharmaceutical Preparation Manufacturing (20 awards) and Research and Development in Physical, Engineering, and Life Sciences (5 awards), consistent with its mission-critical role in supporting preclinical and IND-enabling drug development for federal research institutes.

Quick answers

Is Alchem Laboratories Corporation registered in SAM.gov?

Alchem Laboratories Corporation's SAM.gov registration expired on September 16, 2026.

Which contract vehicles does Alchem Laboratories Corporation hold?

Alchem Laboratories Corporation holds a place on 5 federal contract vehicles, including Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products and Preclinical Services for HIV Therapeutics.

How much has Alchem Laboratories Corporation received in federal contracts?

Federal contracts obligated $406,478 to Alchem Laboratories Corporation in fiscal year 2025.

What is Alchem Laboratories Corporation's most recent federal award?

Alchem Laboratories Corporation's most recent federal contract award is The non-GMP synthesis of compounds for drug discovery (75N91026F00001), from National Cancer Institute (NIH), on September 20, 2026.

On GovTribe

See Alchem Laboratories Corporation's full federal record

  • Federal contract awards
  • IDV awards
  • Contract vehicles
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors